Allergic rhinitis

Cover Page

Cite item

Full Text

Abstract

Allergic rhinitis is one of the most common diseases (~10%–24% of the population experience allergic rhinitis in the Russian Federation) occurring in the population regardless of sex and age. The urgency of the problem is associated with an increase in the number of patients and the fact that allergic rhinitis is considered a risk factor for the development of asthma.

The clinical allergic rhinitis guideline aimed to optimize patient care, up-to-date information about the epidemiology, and disease etiology and pathogenesis. Herein, we present the actual data about the allergic rhinitis classification and its clinical signs and modern (clinical, laboratory, and instrumental) and differential diagnostics. Studies reported allergic rhinitis treatment, rehabilitation, and prevention in the guidelines. The authors describe in detail the existing healthcare options for patients with allergic rhinitis, diagnostic features, and care in partial groups of population (children and pregnant women). The clinical guidelines are recommended for medical doctors (independently from qualification), under- and postgraduate students, universities tutors, residents, and researchers.

About the authors

Natalia G. Astafieva

Saratov State Medical University named after V.I. Razumovsky

Email: astang@mail.ru
ORCID iD: 0000-0002-7691-4584
SPIN-code: 9941-7013

MD, Dr. Sci. (Med.), Professor

Russian Federation, Saratov

Alexander A. Baranov

Research Institute of Pediatrics and Children’s Health of Central Clinical Hospital of the Russian Academy of Sciences

Email: baranov@pediatr-russia.ru
ORCID iD: 0000-0003-3987-8112
SPIN-code: 3570-1806

MD, Dr. Sci. (Med.), Professor, Academician of the Russian Academy of Sciences

Russian Federation, Moscow

Elena A. Vishneva

Research Institute of Pediatrics and Children’s Health of Central Clinical Hospital of the Russian Academy of Sciences; Pirogov Russian National Research Medical University

Email: vishneva.e@yandex.ru
ORCID iD: 0000-0001-7398-0562
SPIN-code: 1109-2810

MD, Dr. Sci. (Med)

Russian Federation, Moscow; Moscow

Nikolay A. Daihes

The National Medical Research Center for Otorhinolaryngology of the Federal Medico-Biological Agency of Russia

Email: admin@otolar.ru
ORCID iD: 0000-0001-5636-5082
SPIN-code: 6943-2426

MD, Dr. Sci. (Med.), Professor

Russian Federation, Moscow

Alexander V. Zhestkov

Samara State Medical University

Email: avzhestkov2015@yandex.ru
ORCID iD: 0000-0002-3960-830X
SPIN-code: 2765-9617

MD, Dr. Sci. (Med.), Professor

Russian Federation, Samara

Natalya I. Ilina

National Research Center ― Institute of Immunology Federal Medical-Biological Agency of Russia

Email: instimmun@yandex.ru
ORCID iD: 0000-0002-3556-969X
SPIN-code: 6715-5650

MD, Dr. Sci. (Med.), Professor

Russian Federation, 24, Kashirskoe shosse, Moscow, 115522

Olga V. Karneeva

The National Medical Research Center for Otorhinolaryngology of the Federal Medico-Biological Agency of Russia; Pirogov Russian National Research Medical University

Email: olya.karneeva@yandex.ru
ORCID iD: 0000-0002-5721-1699
SPIN-code: 5461-1031

MD, Dr. Sci. (Med.), Associate Professor

Russian Federation, Moscow; Moscow

Elena P. Karpova

Russian Medical Academy of Continuous Professional Education

Email: edoctor@mail.ru
ORCID iD: 0000-0002-4062-8957
SPIN-code: 1089-0533

MD, Dr. Sci. (Med.), Professor

Russian Federation, Moscow

Irina A. Kim

The National Medical Research Center for Otorhinolaryngology of the Federal Medico-Biological Agency of Russia; Pirogov Russian National Research Medical University

Email: irinakim_s@mail.ru
ORCID iD: 0000-0003-1078-6388
SPIN-code: 7493-1032

MD, Dr. Sci. (Med.)

Russian Federation, Moscow; Moscow

Andrey I. Kryukov

The Sverzhevskiy Otorhinolaryngology Healthcare Research Institute; Pirogov Russian National Research Medical University

Email: lorcentr@mtu-net.ru
ORCID iD: 0000-0002-0149-0676
SPIN-code: 9393-8753

MD, Dr. Sci. (Med.), Professor

Russian Federation, Moscow; Moscow

Oksana M. Kurbacheva

National Research Center ― Institute of Immunology Federal Medical-Biological Agency of Russia; Moscow State University of Medicine and Dentistry named after A.I. Evdokimov

Email: kurbacheva@gmail.com
ORCID iD: 0000-0003-3250-0694
SPIN-code: 5698-6436

MD, Dr. Sci. (Med.), Professor

Russian Federation, 24, Kashirskoe shosse, Moscow, 115522; Moscow

Raisa Y. Meshkova

Smolensk State Medical University

Email: Meshkova.raisa@yandex.ru
ORCID iD: 0000-0002-7806-9484
SPIN-code: 8937-1230

MD, Dr. Sci. (Med.), Professor

Russian Federation, Smolensk

Leyla S. Namazova-Baranova

Research Institute of Pediatrics and Children’s Health of Central Clinical Hospital of the Russian Academy of Sciences; Pirogov Russian National Research Medical University

Email: leyla.s.namazova@gmail.com
ORCID iD: 0000-0002-2209-7531
SPIN-code: 1312-2147

MD, Dr. Sci. (Med.), Professor, Academician of the Russian Academy of Sciences

Russian Federation, Moscow; Moscow

Natalia M. Nenasheva

Russian Medical Academy of Continuous Professional Education

Email: 1444031@gmail.com
ORCID iD: 0000-0002-3162-2510
SPIN-code: 3363-6170

MD, Dr. Sci. (Med.), Professor

Russian Federation, Moscow

Gennadiy A. Novik

Saint Petersburg State Pediatric Medical University

Email: ga_novik@mail.ru
ORCID iD: 0000-0002-7571-5460
SPIN-code: 6289-0209

MD, Dr. Sci. (Med.), Professor

Russian Federation, Saint Petersburg

Evgeny V. Nosulya

The Sverzhevskiy Otorhinolaryngology Healthcare Research Institute

Email: Nosulya@bk.ru
ORCID iD: 0000-0002-3897-8384
SPIN-code: 8054-9615

MD, Dr. Sci. (Med.), Professor

Russian Federation, Moscow

Ksenia S. Pavlova

National Research Center ― Institute of Immunology Federal Medical-Biological Agency of Russia

Author for correspondence.
Email: ksenimedical@gmail.com
ORCID iD: 0000-0002-4164-4094
SPIN-code: 7593-0838
Scopus Author ID: 7004658159
ResearcherId: P-9255-2017

MD, Cand. Sci. (Med.), PhD, Leading Researcher, Asthma Department

Russian Federation, 24, Kashirskoe shosse, Moscow, 115522

Alexander N. Pampura

Pirogov Russian National Research Medical University

Email: apamputa1@mail.ru
ORCID iD: 0000-0001-5039-8473
SPIN-code: 9722-7961

MD, Dr. Sci. (Med.), Professor

Russian Federation, Moscow

Valery M. Svistushkin

First Sechenov Moscow State Medical University (Sechenov University)

Email: svvm3@yandex.ru
ORCID iD: 0000-0001-7414-1293
SPIN-code: 9040-5720

MD, Dr. Sci. (Med.), Professor

Russian Federation, Moscow

Liliya R. Selimzyanova

Research Institute of Pediatrics and Children’s Health of Central Clinical Hospital of the Russian Academy of Sciences; First Sechenov Moscow State Medical University (Sechenov University)

Email: lilysir@mail.ru
ORCID iD: 0000-0002-3678-7939
SPIN-code: 5508-1689

MD, Cand. Sci. (Med.), Associate Professor

Russian Federation, Moscow; Moscow

Musa R. Khaitov

National Research Center ― Institute of Immunology Federal Medical-Biological Agency of Russia

Email: mr.khaitov@nrci.ru
ORCID iD: 0000-0003-4961-9640
SPIN-code: 3199-9803

MD, Dr. Sci. (Med.), Professor

Russian Federation, 24, Kashirskoe shosse, Moscow, 115522

Rakhim M. Khaitov

National Research Center ― Institute of Immunology Federal Medical-Biological Agency of Russia

Email: rm.khaitov@nrcii.ru
ORCID iD: 0000-0003-1829-0424
SPIN-code: 4004-6561

MD, Dr. Sci. (Med.), Professor, Academician of the Russian Academy of Sciences

Russian Federation, 24, Kashirskoe shosse, Moscow, 115522

References

  1. Allergology and Immunology: National guidelines. Ed. by R.M. Khaitov, N.I. Ilina. Moscow: GEOTAR-Media; 2009. 656 p. (In Russ).
  2. Ilyina NI, Kurbacheva OM, Pavlova KS, Polner SA. Federal clinical guidelines: Allergic rhinitis. Russian Journal of Allergy. 2017;15(2):47–54. (In Russ).
  3. Khaitov MR, Namazova-Baranova LS, Chuchalin AG, et al. ARIA 2016: Modern directions of medical care for patients with allergic rhinitis in the light of the requirements of precision medicine. Russian Journal of Allergy. 2017;14(3):46–54. (In Russ).
  4. Brozek JL, Bousquet J, Baena-Cagnani CE, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2017 revision. J Allergy Clin Immunol. 2017;140(4):950–958. doi: 10/1016/j/jaci.2017.03.050
  5. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA2LEN and AllerGen). Allergy. 2008;63(Suppl 86):8–160. doi: 10.1111/j.1398-9995.2007.01620.x
  6. Khaitov MR, Namazova-Baranova LS, Ilyina NI, et al. ARIA 2019: algorithms for providing assistance for allergic rhinitis in Russia. Russian Journal of Allergy. 2020;17(1):7–22. (In Russ). doi: 10.36691/RAJ.2020.17.1.001
  7. Wise SK, Lin SY, Toskala E, et al. International consensus statement on allergy and rhinology: allergic rhinitis. Int Forum Allergy Rhinol. 2018;8(2):108–352. doi: 10.1002/alr.22073
  8. Global atlas of allergy. Editors: Cezmi A. Akdis, Ioana Agache. Published by the European Academy of Allergy and Clinical Immunology. 2014. 388 р.
  9. Gushchin IS. Allergic inflammation and its pharmacological control. Moscow: Farmarus Print; 1998. 250 р. (In Russ).
  10. Ilyina NI, Kurbacheva OM, Pavlova KS, Ilyina EV. Screening epidemiological study (GA2LEN) for the detection of allergic diseases and respiratory diseases in Russia. Russian Journal of Allergy. 2009;(3):486–487. (In Russ).
  11. Ilyina NI, Luss LV, Kurbacheva OM, et al. The influence of climatic factors on the spectrum and structure of allergic diseases on the example of the Moscow region. Russian Journal of Allergy. 2014;(2):25–31. (In Russ).
  12. Khaitov RM, Ilyina NI, Kurbacheva OM, Pavlova KS. Traditions, achievements and innovations in modern allergology. Physiology Pathology Immune System. 2010;14(1):3–14. (In Russ).
  13. Asher MI, Weiland SK. The International Study of Asthma and Allergies in Childhood (ISAAC). ISAAC Streering Committee. Clin Exp Allergy. 1998;28(Suppl 5):52–66. dis. 90-1. doi: 10.1046/j.1365-2222.1998.028s5052.x
  14. Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J. 2004;24(5):758–764. doi: 10.1183/09031936.04.00013904
  15. Van Cauwenberge PB, Ciprandi G, Vermeiren JS. Epidemiology of allergic rhinitis. The UCB Institute of Allergy. Brussel; 2001. 27 р.
  16. Pawankar R, Canonica GW, Holgate ST, et al. The World Allergy Organization White Book on Allergy; 2013.
  17. Corren J. The impact of allergic rhinitis on bronchial asthma. J Allergy Clin Immunol. 1998;101(2 Pt 2):S352–356. doi: 10.1016/s0091-6749(98)70218-0
  18. Gergen PJ, Turkeltaub PC. The association of individual allergen reactivity with respiratory disease in a national sample: data from the second National Health and Nutrition Examination Survey, 1976-80 (NHANES II). J Allergy Clin Immunol. 1992;90(4 Pt 1):579–588. doi: 10.1016/0091-6749(92)90130-t
  19. Greisner W, Settipane RJ, Settipane GA. Co-existence of asthma and allergic rhinitis: a 23-year follow-up study of college students. Allergy Asthma Proc. 1998;19(4):185–188. doi: 10.2500/108854198778557836
  20. Guerra S, Sherrill DL, Martinez FD, Barbee RA. Rhinitis as an independent risk factor for adult-onset asthma. J Allergy Clin Immunol. 2002;109(3):419–425. doi: 10.1067/mai.2002.121701
  21. Tohidinik HR, Mallah N, Takkouche B. History of allergic rhinitis and risk of asthma; a systematic review and meta-analysis. World Allergy Organ J. 2019;12(10):100069. doi: 10.1016/j.waojou.2019.100069
  22. Vignola AM, Chanez P, Godard P, Bousquet J. Relationships between rhinitis and asthma. Allergy. 1998;53(9):833–839. doi: 10.1111/j.1398-9995.1998.tb03988.x
  23. Rondón C, Campo P, Togias A, et al. Local allergic rhinitis: concept, pathophysiology, and management. J Allergy Clin Immunol. 2012;129(6):1460–1467. doi: 10.1016/j.jaci.2012.02.032
  24. Kurbacheva OM, Pavlova KS. Allergic rhinitis and allergic conjunctivitis: one disease — two clinical forms. Russ Allergolog J. 2015;(3):22–29. (In Russ).
  25. Thomas M. Allergic rhinitis: evidence for impact on asthma. BMC Pulmonary Medicine. 2006;6(Suppl 1):S4. doi: 10.1186/1471-2466-6-S1-S4
  26. Poorey VK, Soni S, Thakur P, Gupta A. Effect of nasal allergy over spirometric parameters: a prospective study. Indian J Otolaryngol Head Neck Surg. 2016;68(1):6–10. doi: 10.1007/s12070-015-0876-x
  27. Togias A. Unique mechanistic features of allergic rhinitis. J Allergy Clin Immunol. 2000;105(6 Pt 2):S599–S604. doi: 10.1067/mai.2000.106885
  28. Kurbacheva OM, Pavlova KS, Galitskaya MA. Allergen-specific immunotherapy. Analytical review of modern international and domestic positional documents. Russ Allergolog J. 2017;14(1):24–32. (In Russ).
  29. Calderón MA, Casale TB, Togias A, et al. Allergen-specific immunotherapy for respiratory allergies: from meta-analysis to registration and beyond. J Allergy Clin Immunol. 2011;127(1):30–38. doi: 10.1016/j.jaci.2010.08.024
  30. Jacobsen L, Niggemann B, Dreborg S, et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10 year follow-up on the PAT study. Allergy. 2007;62(8):943–948. doi: 10.1111/j.1398-9995.2007.01451.x
  31. Jutel M, Agache I, Bonini S, et al. Internetional Consensus On (ICON) Allergy Immunotherapy (AIT). J Allergy Clin Immunol. 2015;136(3):556–568. doi: 10.1016/j.jaci.2015.04.047
  32. Moller C, Dreborg S, Ferdousi HA, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol. 2002; 109(2):251–256. doi: 10.1067/mai.2002.121317
  33. Niggemann B, Jacobsen L, Dreborg S, et al. Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children. Allergy. 2006;61(7):855–859. doi: 10.1111/j.1398-9995.2006.01068.x
  34. Papadopoulos NG, Arakawa H, Carlsen KH, et al. International consensus on (ICON) pediatric asthma. Allergy. 2012;67(8):976–997. doi: 10.1111/j.1398-9995.2012.02865.x
  35. Zielen S, Devillier P, Heinrich J, et al. Sublingual immunotherapy provides long-term relief in allergic rhinitis and reduces the risk of asthma: a retrospective, real-world database analysis. Allergy. 2018;73(1):165–177. doi: 10.1111/all.13213
  36. Bousquet PJ, Combescure C, Neukirch F, et al. Visual analog scales can assess the severity of rhinitis graded according to ARIA guidelines. Allergy. 2007;62 (4):367–372. doi: 10.1111/j.1398-9995.2006.01276.x
  37. Bousquet J, Schunemann HJ, Hellings PW, et al. MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. J Allergy Clin Immunol. 2016;138(2):367–374.e2. doi: 10.1016/j.jaci.2016.03.025
  38. Courbis AL, Murray RB, Arnavielhe S, et al. Electronic Clinical Decision Support System for allergic rhinitis management: MASK e-CDSS. Clin Exp Allergy. 2018;48(12):1640–1653. doi: 10.1111/cea.13230
  39. Tyufin DS, Deev IA, Kobyakova OS, et al. Control of allergic rhinitis: modern assessment tools. Bulletin Siberian Med. 2019; 18(2):262–273. (In Russ). doi: 10.20538/1682-0363-2019-2-262-273
  40. Papadopoulos NG, Bernstein JA, Demoly P, et al. Phenotypes and endotypes of rhinitis and their impact on management: a PRACTALL report. Allergy. 2015;70(5):474–494. doi: 10.1111/all.12573
  41. Droste JH, Kerhof M, de Monchy JG, et al. Association of skin test reactivity, specific IgE, total IgE, and eosinophils with nasal symptoms in a community-based population study. The Dutch ECRHS Group. J Allergy Clin Immunol. 1996;97(4):922–932. doi: 10.1016/s0091-6749(96)80066-2
  42. Di Lorenzo G, Pacor ML, Amodio E, et al. Differences and similarities between allergic and nonallergic rhinitis in a large sample of adult patients with rhinitis symptoms. Int Arch Allergy Immunol. 2011;155(3):263–270. doi: 10.1159/000320050
  43. Gelardi M, Passalacqua G, Fiorella ML, Quaranta N. Assessment of biofilm by nasal cytology in different forms of rhinitis and its functional correlations. Eur Ann Allergy Clin Immunol. 2013;45(1):25–29.
  44. Gelardi M, Peroni DG, Incorvaia C, et al. Seasonal changes in nasal cytology in mite-allergic patients. J Inflamm Res. 2014;7: 39–44. doi: 10.2147/JIR.S54581
  45. Park SC, Kim JH, Lee KH, et al. Association of serum eosinophilia and total immunoglobulin E concentration with the risk of allergic symptoms and allergic sensitization, respectively: a 2-year follow-up study. Int J Pediatr Otorhinolaryngol. 2016;86:167–171. doi: 10.1016/j.ijporl.2016.05.005
  46. Tay TR, Bosco J, Aumann H, et al. Elevated total serum immunoglobulin E (≥1000 IU/mL): implications? Intern Med J. 2016; 46(7):846–849. doi: 10.1111/imj.13073
  47. Satwani H, Rehman A, Ashraf S, Hassan A. Is serum total IgE levels a good predictor of allergies in children? J Pak Med Assoc. 2009;59(10):698–702.
  48. Tu YL, Chang SW, Tsai HJ, et al. Total serum IgE in a population-based study of Asian children in Taiwan: reference value and significance in the diagnosis of allergy. PLoS One. 2013;8(11):e80996. doi: 10.1371/journal.pone.0080996
  49. Ameli F, Brocchetti F, Tosca MA, et al. Nasal endoscopy in children with suspected allergic rhinitis. Laryngoscope. 2011;121(10): 2055–2059. doi: 10.1002/lary.22156
  50. Eren E, Aktas A, Arslanoglu S, et al. Diagnosis of allergic rhinitis: inter-rater reliability and predictive value of nasal endoscopic examination: a prospective observational study. Clin Otolaryngol. 2013;38(6):481–486. doi: 10.1111/coa.12171
  51. Jareoncharsri P, Thitadilok V, Bunnag C, et al. Nasal endoscopic findings in patients with perennial allergic rhinitis. Asian Pac J Allergy Immunol. 1999;17(4):261–267.
  52. Brunner JP, Jawad BA, McCoul ED. Polypoid change of the middle turbinate and paranasal sinus polyposis are distinct entities. Otolaryngol Head Neck Surg. 2017;157(3):519–523. doi: 10.1177/0194599817711887
  53. Tschopp JM, Sistek D, Schindler C, et al. Current allergic asthma and rhinitis: diagnostic efficiency of three commonly used atopic markers (IgE, skin prick tests, and Phadiatop). Results from 8329 randomized adults from the SAPALDIA Study. Swiss study on air pollution and lung diseases in adults. Allergy. 1998;53(6):608–613. doi: 10.1111/j.1398-9995.1998.tb03937.x
  54. Nevis IF, Binkley K, Kabali C. Diagnostic accuracy of skin-prick testing for allergic rhinitis: a systematic review and meta-analysis. Allergy Asthma Clin Immunol. 2016;12:20. doi: 10.1186/s13223-016-0126-0
  55. Health Quality Ontario. Skin Testing for Allergic Rhinitis: A Health Technology Assessment. Ont Health Technol Assess Ser. 2016;16(10):1–45.
  56. Nevis IF, Binkley K., Kabali C. Diagnostic accuracy of skin-prick testing for allergic rhinitis: a systematic review and meta-analysis. Allergy Asthma Clin Immunol. 2016;12:20. doi: 10.1186/s13223-016-0126-0
  57. Liu CY, Zhang Y, Han DM, Zhang L. Evaluation of serum specific IgE for the diagnosis of allergic rhinitis with multi-allergens. Chin Med J (Engl). 2010;123(20):2836–2841.
  58. Jiang XD, Li GY, Dong Z, Zhu DD. Correlation analysis of two serum-specific immunoglobulin E test systems and skin-prick test in allergic rhinitis patients from northeast China. Am J Rhinol Allergy. 2011;25(2):116–119. doi: 10.2500/ajra.2011.25.3572
  59. Cox L. Overview of serological-specific IgE antibody testing in children. Curr Allergy Asthma Rep. 2011;11(6):447–453. doi: 10.1007/s11882-011-0226-3
  60. Hamilton RG, Oppenheimer J. Serological IgE Analyses in the Diagnostic Algorithm for Allergic Disease. J Allergy Clin Immunol Pract. 2015;3(6):833–842. doi: 10.1016/j.jaip.2015.08.016
  61. Steering Committee Authors; Review Panel Members. A WAO-ARIA-GA2LEN consensus document on molecular-based allergy diagnosis (PAMD@: Update 2020. World Allergy Organ J. 2020;13(2):100091. doi: 10.1016/j.waojou.2019.100091
  62. Ferrer M, Sanz ML, Sastre J, et al. Molecular diagnosis in Allergology: application of the microarray technique. J Investig Allergol Clin Immunol. 2009;19(Suppl 1):19–24.
  63. Akdis CA, Jutel M, Akdis M. Regulatory effects of histamine and histamine receptor expression in human allergic immune responses. Chem Immunol Allergy. 2008;94:67–82. doi: 10.1159/000154858
  64. Allocco FT, Votypka V, De Tineo M, et al. Effects of fexofenadine on the early response to nasal allergen challenge. Ann Allergy Asthma Immunol. 2002;89(6):578–584. doi: 10.1016/S1081-1206(10)62105-9
  65. Benninger M, Farrar JR, Blaiss M, et al. Evaluating approved medications to treat allergic rhinitis in the United States: an evidence-based review of efficacy for nasal symptoms by class. Ann Allergy Asthma Immunol. 2010;104(1):13–29. doi: 10.1016/j.anai.2009.11.020
  66. Berger WE, Lumry WR, Meltzer EO, Pearlman DS. Efficacy of desloratadine, 5 mg, compared with fexofenadine, 180 mg, in patients with symptomatic seasonal allergic rhinitis. Allergy Asthma Proc. 2006;27(3):214–223. doi: 10.2500/aap.2006.27.2851
  67. Bocsan CI, Bujor AI, Miron N, et al. In vivo anti-inflammatory effect of H1 antihistamines in allergic rhinitis: a randomized clinical trial. Balkan Med J. 2015;32(4):352–358. doi: 10.5152/balkanmedj.2015.15884
  68. Bousquet J, Bachert C, Canonica GW, et al.; ACCEPT-1 Study Group. Efficacy of desloratadine in intermittent allergic rhinitis: a GA2LEN study. Allergy. 2009;64(10):1516–1523. doi: 10.1111/j.1398-9995.2009.02115.x
  69. Canonica GW, Tarantini F, Compalati E, Penagos M. Efficacy of desloratadine in the treatment of allergic rhinitis: a meta-analysis of randomized, double-blind, controlled trials. Allergy. 2007;62(4): 359–366. doi: 10.1111/j.1398-9995.2006.01277.x
  70. De Blic J, Wahn U, Billard E, et al. Levocetirizine in children: evidenced efficacy and safety in a 6-week randomized seasonal allergic rhinitis trial. Pediatr Allergy Immunol. 2005;16(3):267–275. doi: 10.1111/j.1399-3038.2005.00216.x
  71. Dykewicz MS, Wallace DV, Baroody F, et al. Treatment of seasonal allergic rhinitis: An evidence-based focused 2017 guideline update. Ann Allergy Asthma Immunol. 2017;119(6):489–511.e41. doi: 10.1016/j.anai.2017.08.012
  72. Farré M, Pérez-Mañá C, Papaseit E, et al. Bilastine vs. hydroxyzine: occupation of brain histamine H1-receptors evaluated by positron emission tomography in healthy volunteers. Br J Clin Pharmacol. 2014;78(5):970–980. doi: 10.1111/bcp.12421
  73. Gillman S, Gillard M, Strolin Benedetti M. The concept of receptor occupancy to predict clinical efficacy: a comparison of second generation H1 antihistamines. Allergy Asthma Proc. 2009;30(4): 366–376. doi: 10.2500/aap.2009.30.3226
  74. Leurs R, Church MK, Taglialatela M. H1-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allergy. 2002;32(4):489–498. doi: 10.1046/j.0954-7894.2002.01314.x
  75. Lukat K, Rivas P, Roger A, et al. A direct comparison of efficacy between desloratadine and rupatadine in seasonal allergic rhinoconjunctivitis: a randomized, double-blind, placebo-controlled study. J Asthma Allergy. 2013;(6):31–39. doi: 10.2147/JAA.S39496
  76. Mösges R, König V, Köberlein J. The effectiveness of modern antihistamines for treatment of allergic rhinitis — an IPD meta-analysis of 140,853 patients. Allergol Int. 2013;62(2):215–222. doi: 10.2332/allergolint.12-OA-0486
  77. Muntean A, Bocsan I, Deleanu DM. The effect of H1-antihistamines on allergic inflammation in patients with allergic rhinitis. Human Veterinary Med. 2016, 8(4):161–165.
  78. Naclerio RM. The effect of antihistamines on the immediate allergic response: a comparative review. Otolaryngol Head Neck Surg. 1993,108(6):723–730. doi: 10.1177/019459989310800615
  79. Okubo K, Suzuki T, Tanaka A, Aoki H. Efficacy and safety of rupatadine in Japanese patients with seasonal allergic rhinitis: a double-blind, randomized, multicenter, placebo-controlled clinical trial. Allergol Int. 2019;68(2):207–215. doi: 10.1016/j.alit.2018.08.011
  80. Valk P, Jetten A, Simons R, et al. Effects of a single oral dose of bilastine 20 mg on flying ability in healthy volunteers under conditions of simulated cabin pressure. Allergy: Eur J Allergy Clin Immunol. 2015;(70):647.
  81. Ilina NI, Pavlova KS. Antihistamine, anti-inflammatory and anti-allergic properties of desloratadine. Consilium Medicum. 2015; 17(3):79–83. (In Russ).
  82. Church MK, Maurer M, Simons FE, et al. Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper. Allergy. 2010;65(4):459e466. doi: 10.1111/j.1398-9995.2009.02325.x
  83. Simons FE. Advances in H1-antihistamines. N Engl J Med. 2004; 351(21):2203–2217. doi: 10.1056/NEJMra033121
  84. Castillo M, Scott NW, Mustafa MZ, et al. Topical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis. Cochrane Database Syst Rev. 2015;6:CD009566. doi: 10.1002/14651858.CD009566.pub2
  85. Lee TA, Pickard AS. Meta-analysis of azelastine nasal spray for the treatment of allergic rhinitis. Pharmacotherapy. 2007;27(6): 852–859. doi: 10.1592/phco.27.6.852
  86. Al Sayyad JJ, Fedorowicz Z, Alhashimi D, Jamal A. Topical nasal steroids for intermittent and persistent allergic rhinitis in children. Cochrane Database Syst Rev. 2007;1:CD003163. doi: 10.1002/14651858.CD003163.pub4
  87. Dibildox J. Safety and efficacy of mometasone furoate aqueous nasal spray in children with allergic rhinitis: results of recent clinical trials. J Allergy Clin Immunol. 2001;108(1 Suppl):S54–S58. doi: 10.1067/mai.2001.115567
  88. Herman H. Once-daily administration of intranasal corticosteroids for allergic rhinitis: a comparative review of efficacy, safety, patient preference, and cost. Am J Rhinol. 2007;21(1):70–79. doi: 10.2500/ajr.2007.21.2896
  89. Penagos M, Compalati E, Tarantini F, et al. Efficacy of mometasone furoate nasal spray in the treatment of allergic rhinitis: meta-analysis of randomized, double-blind, placebocontrolled, clinical trials. Allergy. 2008;63(10):1280–1291. doi: 10.1111/j.1398-9995.2008.01808.x
  90. Rodrigo GJ, Neffen H. Efficacy of fluticasone furoate nasal spray vs. placebo for the treatment of ocular and nasal symptoms of allergic rhinitis: a systematic review. Clin Exp Allergy. 2011;41(2):160–170. doi: 10.1111/j.1365-2222.2010.03654.x
  91. Wu EL, Harris WC, Babcock CM, et al. Epistaxis risk associated with intranasal corticosteroid sprays: a systematic review and meta-analysis. Otolaryngol Head Neck Surg. 2019;161(1):18–27. doi: 10.1177/0194599819832277
  92. Yanez A, Rodrigo GJ. Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis. Ann Allergy Asthma Immunol. 2002;89(5):479–484. doi: 10.1016/S1081-1206(10)62085-6
  93. Zieglmayer P, Zieglmayer R, Bareille P, et al. Fluticasone furoate versus placebo in symptoms of grass-pollen allergic rhinitis induced by exposure in the Vienna Challenge Chamber. Curr Med Res Opin. 2008;24(6):1833–1840. doi: 10.1185/03007990802155792
  94. DeWester J, Philpot EE, Westlund RE, et al. The efficacy of intranasal fluticasone propionate in the relief of ocular symptoms associated with seasonal allergic rhinitis. Allergy Asthma Proc. 2003;24(5):331–337.
  95. Bielory L, Chun Y, Bielory BP, Canonica GW. Impact of mometasone furoate nasal spray on individual ocular symptoms of allergic rhinitis: a meta-analysis. Allergy. 2011;66(5):686–693. doi: 10.1111/j.1398-9995.2010.02543.x
  96. Bousquet J, Meltzer EO, Couroux P, et al. Onset of action of the fixed combination intranasal azelastine-fluticasone propionate in an allergen exposure chamber. J Allergy Clin Immunol Pract. 2018;6(5):1726–1732. doi: 10.1016/j.jaip.2018.01.031
  97. Debbaneh PM, Bareiss AK, Wise SK, McCoul ED. Intranasal azelastine and fluticasone as combination therapy for allergic rhinitis: systematic review and meta-analysis. Otolaryngol Head Neck Surg. 2019;161(3):412–418. doi: 10.1177/0194599819841883
  98. Hampel FC, Ratner PH, Van Bavel J, et al. Double-blind, placebo-controlled study of azelastine and fluticasone in a single nasal spray delivery device. Ann Allergy Asthma Immunol. 2010;105(2):168–173. doi: 10.1016/j.anai.2010.06.008
  99. Wei C. The efficacy and safety of H1-antihistamine versus Montelukast for allergic rhinitis: a systematic review and meta-analysis. Biomed Pharmacother. 2016;(83):989–997. doi: 10.1016/j.biopha.2016.08.003
  100. Lu Y, Yin M, Cheng L. [Meta-analysis of leukotriene receptor antagonist montelukast in the treatment of allergic rhinitis. (In Chinese)]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2014;49(8):659–667.
  101. Modgill V, Badyal DK, Verghese A. Efficacy and safety of montelukast add-on therapy in allergic rhinitis. Methods Findings Exp Clin Pharmacol. 2010;32(9):669–674. doi: 10.1358/mf.2010.32.9.1533686
  102. Ngamphaiboon J. Montelukast in general pediatric practices. J Med Assoc Thai. 2005;88(Suppl 4):S348–S351.
  103. Seresirikachorn K, Chitsuthipakorn W, Kanjanawasee D, et al. Leukotriene receptor antagonist addition to h1-antihistamine is effective for treating allergic rhinitis: a systematic review and meta-analysis. Am J Rhinol Allergy. 2019;33(5):591–600. doi: 10.1177/1945892419844459
  104. Xu Y, Zhang J, Wang J. The efficacy and safety of selective h1-antihistamine versus leukotriene receptor antagonist for seasonal allergic rhinitis: a meta-analysis. PLoS One. 2014;9(11):e112815. doi: 10.1371/journal.pone.0112815
  105. Nayak A. A review of montelukast in the treatment of asthma and allergic rhinitis. Expert Opin Pharmacother. 2004;5(3):679–686. doi: 10.1517/14656566.5.3.679
  106. Polos PG. Montelukast is an effective monotherapy for mild asthma and for asthma with co-morbid allergic rhinitis. Prim Care Respir J. 2006;15(5):310–311; author reply 311-2. doi: 10.1016/j.pcrj.2006.07.003
  107. Watts K, Chavasse RJ. Leukotriene receptor antagonists in addition to usual care for acute asthma in adults and children. Cochrane Database Syst Rev. 2012;5:CD006100. doi: 10.1002/14651858.CD006100.pub2
  108. Khattiyawittayakun L, Seresirikachorn K, Chitsuthipakorn W, et al. Effects of decongestant addition to intranasal corticosteroid for chronic rhinitis: a systematic review and meta-analysis. Int Forum Allergy Rhinol. 2018;8(12):1445–1453. doi: 10.1002/alr.22193
  109. Yoo JK, Seikaly H, Calhoun KH. Extended use of topical nasal decongestants. Laryngoscope. 1997;107(1):40–43. doi: 10.1097/00005537-199701000-00010
  110. Okubo K, Okano M, Sato N, Tamaki Y. Efficacy of omalizumab for severe allergic rhinitis induced by japanese cedar pollen in patients treated with combination oral antihistamines and nasal corticosteroids. J Allergy Clin Immunol. 2019;143(2):AB424. doi: 10.1016/j.jaci.2018.12.955
  111. European Academy of Allergy & Clinical Immunology. Okubo K., et al. Poster presented at The EAACI. June 1–6, 2019, Lisbon, Poster#L1372. Available from: https://www.eaaci.org/eaaci-congresses/eaaci-2019/e-posters. Accessed: 22.02.2022.
  112. Tsabouri S, Tseretopoulou X, Priftis K, et al. Omalizumab for the treatment of inadequately controlled allergic rhinitis: a systematic review and meta-analysis of randomized clinical trials. J Allergy Clin Immunol. 2014;2(3):332–340. doi: 10.1016/j.jaip.2014.02.001
  113. Yu C, Wang K, Cui X, et al. Clinical efficacy and safety of omalizumab in the treatment of allergic rhinitis: a systematic review and meta-analysis of randomized clinical trials. Am J Rhinol Allergy. 2020;34(2):196–208. doi: 10.1177/1945892419884774
  114. Kilburn SA, Lasserson TJ, McKean MC. Pet allergen control measures for allergic asthma in children and adults. Cochrane Database Syst Rev. 2001;1:CD002989. doi: 10.1002/14651858.CD002989
  115. Sheikh A, Hurwitz B, Nurmatov U, van Schayck CP. House dust mite avoidance measures for perennial allergic rhinitis. Cochrane Database Syst Rev. 2010;7:CD001563. doi: 10.1002/14651858.CD001563.pub3
  116. Head K, Snidvongs K, Glew S, et al. Saline irrigation for allergic rhinitis. Cochrane Database Syst Rev. 2018;6(6):CD012597. doi: 10.1002/14651858.CD012597.pub2
  117. Hermelingmeier KE, Weber RK, Hellmich M, et al. Nasal irrigation as an adjunctive treatment in allergic rhinitis: a systematic review and meta-analysis. Am J Rhinol Allergy. 2012;26(5): e119–e125. doi: 10.2500/ajra.2012.26.3787
  118. Li CL, Lin HC, Lin CY, Hsu TF. Effectiveness of hypertonic saline nasal irrigation for alleviating allergic rhinitis in children: a systematic review and meta-analysis. J Clin Med. 2019;8(1):64. doi: 10.3390/jcm8010064
  119. Valerieva A, Church MK, Staevska M, et al. Micronized cellulose powder as a means to enhance intranasal symptoms-driven treatment: patients” attitudes in a real life setting. Allergy. 2016;71:13.
  120. Kurbacheva OM, Pavlova KS. Federal clinical guidelines. Allergen-specific immunotherapy. Russian Journal of Allergy. 2006;(4-5):55–61. (In Russ).
  121. Des Roches A, Paradis L, Menardo JL, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol. 1997;99(4):450–453. doi: 10.1016/s0091-6749(97)70069-1
  122. Dhami S, Nurmatov U, Arasi S, et al. Allergen immunotherapy for allergic rhinoconjunctivitis: A systematic review and meta-analysis. Allergy. 2017;72(11):1597–1631. doi: 10.1111/all.13201
  123. Feng B, Wu J, Chen B, et al. Efficacy and safety of sublingual immunotherapy for allergic rhinitis in pediatric patients: a meta-analysis of randomized controlled trials. Am J Rhinol Allergy. 2017; 31(1):27–35. doi: 10.2500/ajra.2017.31.4382
  124. Kim J.M., Lin S.Y., Suarez-Cuervo C. Allergen-specific immunotherapy for pediatric asthma and rhinoconjunctivitis: a systematic review. Pediatrics. 2013;131(6):1155–1167. doi: 10.1542/peds.2013-0343
  125. Li Y, Yu SY, Tang R, et al. Sublingual immunotherapy tablets relieve symptoms in adults with allergic rhinitis: a meta-analysis of randomized clinical trials. Chin Med J (Engl). 2018;131(21): 2583–2588. doi: 10.4103/0366-6999.244108
  126. Mösges R, Santiago VA, Allekotte S, et al. Subcutaneous immunotherapy with depigmented-polymerized allergen extracts: a systematic review and meta-analysis. Clin Transl Allergy. 2019;9:29. doi: 10.1186/s13601-019-0268-5
  127. Purello-D’Ambrosio F, Gangemi S, Merendino RA, et al. Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study. Clin Exp Allergy. 2001;31(8):1295–1302. doi: 10.1046/j.1365-2222.2001.01027.x
  128. Radulovic S, Calderon MA, Wilson D, Durham S. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev. 2010;12:CD002893. doi: 10.1002/14651858.CD002893.pub2
  129. Tahamiler R, Saritzali G, Canakcioglu S. Long-term efficacy of sublingual immunotherapy in patients with perennial rhinitis. Laryngoscope. 2007;117(6):965–969. doi: 10.1097/MLG.0b013e31804f8141
  130. Wilson DR, Lima MT, Durham SR. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy. 2005;60(1):4–12. doi: 10.1111/j.1398-9995.2005.00699.x
  131. Kurbacheva OM, Pavlova KS, Galitskaya MA, Smirnov DS. Current ideas about the mechanisms of allergen-specific immunotherapy, potential markers of effectiveness and ways of improvement. Russian Journal of Allergy. 2017;14(4-5):5–17.
  132. Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy: multiple suppressor factors at work in immune tolerance to allergens. J Allergy Clin Immunol. 2014;133(3):621–631. doi: 10.1016/j.jaci.2013.12.1088
  133. Pfaar O, Demoly P, Gerth van Wijk R, et al. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper. Allergy. 2014;69(7):854–867. doi: 10.1111/all.12383
  134. Mishra A, Kawatra R, Gola M. Interventions for atrophic rhinitis. Cochrane Database Syst Rev. 2012;15(2):CD008280. doi: 10.1002/14651858.CD008280.pub2
  135. Jose J, Coatesworth AP. Inferior turbinate surgery for nasal obstruction in allergic rhinitis after failed medical treatment. Cochrane Database Syst Rev. 2010;8(12):CD005235. doi: 10.1002/14651858.CD005235.pub2
  136. Feng S, Han M, Fan Y, et al. Acupuncture for the treatment of allergic rhinitis: a systematic review and meta-analysis. Am J Rhinol Allergy. 2015;29(1):57–62. doi: 10.2500/ajra.2015.29.4116
  137. Zhang J, Zhang Y, Huang X, et al. Different acupuncture therapies for allergic rhinitis: overview of systematic reviews and network meta-analysis. Evid Based Complement Alternat Med. 2020;2020:8363027. doi: 10.1155/2020/8363027
  138. Ant K, Pearce N, Anderson HR, et al. Global map of the prevalence of symptoms of rhino-conjunctivitis in children. The International Study of Asthma and Allergies in Childhood ISAAC Phase Three. Allergy. 2009;64(1):123–148. doi: 10.1111/j.1398-9995.2008.01884.x
  139. Maspero JF, Rosenblut A, Finn AJ, et al. Safety and efficacy of fluticasone furoate in pediatric patients with perennial allergic rhinitis. Otolaryngol Head Neck Surg. 2008;138(1):30–37. doi: 10.1016/j.otohns.2007.10.023
  140. Nasser M, Fedorowicz Z, Aljufairi H, McKerrow W. Antihistamines used in addition to topical nasal steroids for intermittent and persistent allergic rhinitis in children. Cochrane Database Syst Rev. 2010;7:CD006989. doi: 10.1002/14651858.CD006989.pub2
  141. Roberts G, Xatzipsalti M, Borrego LM, et al. Paediatric rhinitis: position paper of the European Academy of Allergy and Clinical Immunology. Allergy. 2013;68(9):1102–1116. doi: 10.1111/all.12235
  142. RADAR. Allergic rhinitis in children: recommendations and algorithm for children’s allergic rhinitis. 2nd ed., reprint. and add. Moscow: Original layout; 2017. 80 р. (In Russ).
  143. Lopatin AS. Diagnostics and treatment of rhinitis and rhinosinusitis in pregnant women. Russian Journal of Allergy. 2006;(1):12–18. (In Russ).
  144. Gani F, Braida A, Lombardi C. et al. Rhinitis in pregnancy. Allerg Immunol (Paris). 2003;35(8):306–313.
  145. Kurbacheva OM, Shvets SM. Allergic rhinitis and pregnancy: possibilities of modern therapy. Effect Pharmacother. 2013;(18): 74–80. (In Russ).
  146. Gilbert C, Mazzotta P, Loebstein R, Koren G. Fetal safety of drugs used in the treatment of allergic rhinitis: a critical review. Drug Saf. 2005;28(8):707–719. doi: 10.2165/00002018-200528080-00005
  147. Yawn B, Knudtson M. Treating asthma and comorbid allergic rhinitis in pregnancy. J Am Board Fam Pract. 2007;20:289–298. doi: 10.3122/jabfm.2007.03.060144
  148. Cetirizine Pregnancy and Breastfeeding Warnings. Available from: https://www.drugs.com/breastfeeding/cetirizine.html. Accessed: 22.02.2022.
  149. Kallen B, Olausson OP. Use of anti-asthmatic drugs during pregnancy. 3. Congenital malformations in the infants. Eur J Clin Pharmacol. 2007;63(4):383–388. doi: 10.1007/s00228-006-0259-z

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. B1. Algorithm for managing a patient with allergic rhinitis. Ru

Download (918KB)
Indexing metadata
3. Fig. B1. Algorithm for managing a patient with allergic rhinitis. Eng

Download (871KB)
Indexing metadata
4. Fig. B2. Link to the automated platform access with an algorithm for managing a patient with allergic rhinitis.

Download (213KB)
Indexing metadata
5. Fig. G1. Visual analogue scale.

Download (165KB)
Indexing metadata
6. Fig. G2. Step-by-step algorithm for therapy of previously treated patients using a visual analogue scale (adolescents and adults) [18].

Download (548KB)
Indexing metadata

Copyright (c) 2022 Pharmarus Print Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies